The company also disclosed that it has modified the US regulatory package for its lower respiratory tract diagnostic panel after discussions with the FDA.
The new panel is able to detect up to 130 pathogens that cause severe abdominal infections, such as appendicitis and acute pancreatitis.
The company attributed the decline in part to nonrecurring sales of its Unyvero molecular diagnostic system to partners for clinical trials and regulatory clearances.
Ares plans to use the GEAR database to discover new markers of antibiotic resistance and will eventually develop it as an interpretation service.
Curetis' new subsidiary will focus on using a recently acquired database of bacterial genome sequences to identify novel antibiotic resistance markers.
Curetis recently completed a clinical trial that compared the panel to both microbiology and individual PCR testing plus sequencing.
The firm plans to develop a line of tests on the system that could include panels for infection control, viral testing, CNS infections, and assays for immunocompromised patients.
The deal also includes milestone payments to Carpegen and Systec totaling €2.5M and a potential for €9M in royalty-based earnings.
For the 40-target panel, the trial found an overall average weighted sensitivity and specificity of 90 and 99 percent, respectively.
The company said the cartridge now covers 102 diagnostic targets including 85 pathogens and 17 treatment resistance markers.
Gene drives might run into biological resistance, the Economist reports.
Forensic experts exhumed painter Salvador Dalí's body to collect DNA for a paternity test, CBS News reports.
Yale Environment 360 writes that synthetic and conservation biologists aren't always on the same wavelength, but they are trying to reach an understanding.
In Science this week: full CRISPR locus integration complex structure, and more.